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Background: Injuries to the spinal cord (SCI) are one of the most detrimental 
central nervous system (CNS) injuries in developing countries. Today, 
treatment is one of the major issues facing the medical profession, and to date, 
there is no known promising treatment capable of fully healing injuries. There 
are various methods to repair and improve SCI, including the use of stem cells 
particularly mesenchymal stem cells (MSCs). Various studies have been 
performed on applying these cells in the treatment of SCI, whose results have 
confirmed the efficacy of using these cells specifically due to the paracrine 
secretion of these cells including growth factors, chemokines, cytokines, and 
small extracellular vesicles. Interestingly, among these paracrine molecules, 
exosomes may have the maximum therapeutic value and as such is widely 
investigated by researchers.  
 
Aim: to fully focus on the usage of stem cell-derived extracellular vesicles on 
the healing of SCI in animal models.  
 
Conclusion: Taken together, the extracellular nanovesicles have promising 
therapeutic potentials and their use in the treatment of SCI has been rapidly 
growing. In this review, we elucidated the effect of exosomes derived from 
bone marrow MSCs in SCI.  
 
Conflicts of Interest: The authors declare no conflicts of interest. 
Please cite this article as Khoshsirat S, Abbaszadeh HA, Keramatinia A, Khoramgah M, Vafaei-Nezhad S, Niknazar S, 
Darabi S, Tahmasebinia F, Peyvandi H. Exosome Therapy in Spinal Cord Injury: A Review. J Otorhinolaryngol Facial 
Plast Surg. 2019;5(2):1-8. https://doi.org/10.22037/ORLFPS.v5i2.28004 
 
Introduction 
Spinal Cord Injury (SCI) today is one of the 
most debilitating neurological injuries in 
societies, and several victims of SCI may die 
before reaching the hospital. People who are 
hospitalized are also at risk of dying from 
infection after one year. It also imposes huge 
costs on governments and families. Studies 
suggest that the most common cause of SCIs is 
traffic accidents. Despite the current 
treatments to eliminate the complications of 
SCI, no definite cure has been found so far. 
Complications after CNS injury, especially the 
spinal cord, are one of the most important 
challenges facing the healthcare sector in both 
developed and developing countries. The 
annual incidence of SCI around the world has 
been reported to range from 3.6 to 195 cases 
per million. This injury is reported to be more 
common in men than in women (1). In Iran, 
the prevalence of SCI is 318 per million (2). 
This injury can partially or completely destroy 
the three main actions of the spinal cord, 
including movement, sensation, and reflexes 
(1, 3, 4). Functional defects are caused by 
damages to axonal fringes, loss of neurons, 
activation of astrocytes and microglia, and 
degeneration of oligodendrocytes (5). 
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Although treatments such as drug therapy, 
gene therapy, cell therapy hypothermia, and 
tissue-engineering scaffolds have been studied 
to induce repair, none of them have completely 
eliminated the side effects so far (6).  
SCI has primary and secondary phases. The 
primary phase occurs due to mechanical 
pressure while the second phase may occur 
after the initial phase, following the onset of 
inflammatory cascades (7, 8). Studies have 
shown that free radical formation and lipid 
peroxidation in SCI causes a rapid and severe 
oxidative stress and neuroinflammatory 
response which may result in neuronal death 
and decreased blood flow causing edema and 
inflammation (9, 10). Thus, inflammation as a 
key factor in SCI is due to the activation of 
microglia and releasing pro-inflammatory 
cytokines which may cause neuronal damage 
(8, 11-14). Different pharmacological 
therapies can partially control the secondary 
phase of SCI by preventing the production of 
inflammatory factors and free radicals, which 
can reduce the complications in SCI models. 
MSC-based therapies in SCI and their 
associated barriers 
One of the promising therapies in the 
treatment of SCI is the use of stem cells (7, 15-
19). MSCs are multipotent cells that can be 
obtained from a variety of sources including 
bone marrow, peripheral blood, cord blood, 
and adipose tissue. Today these cells serve as a 
promising source for the cellular treatment of 
damaged cells (20-25). Basically, the 
therapeutic application of these cells after SCI 
can reduce the volume of cavities created in 
the spinal cord, replace dead cells, and create a 
favorable environment for axonal repair (26). 
Studies on rodents have shown that MSCs 
cells can contribute to the expression of factors 
such as neurotrophins, germination, and 
axonal regrowth. They can also lead to the 
healing of damaged tissues by improving 
vascular blood flow (27, 28). Research has 
also shown that the beneficial therapeutic 
effects of these cells are due to their paracrine 
secretion, but the precise mechanism of their 
efficacy has not yet been elucidated. One of 
the frequently mentioned barriers to MSCs 
application is their large size and inability to 
cross the blood-brain barrier, as well as their 
poor survival at the site of the injury; they 
disappear shortly after due to paracrine 
secretions of these cells, such as the secretion 
of molecules such as growth factors, 
chemokines, cytokines and small extracellular 
vesicles (23, 24, 29-32). 
Extracellular vesicles and their potential 
role  
Extracellular vesicles are membrane-bound 
structures that can be secreted into the 
extracellular space by most cells. Evidence 
suggests that these structures play an important 
role in intercellular communication in 
physiological and pathological processes (33, 
34). These vesicles are classified into 
exosomes (30 to 100 nm), microsomes or 
ectosomes (50 nm to 1 μm), and apoptotic 
bodies (50 nm to 5 μm) based on their 
intracellular origin and size. Exosomes are 
released through the attachment of 
multivesicular bodies (MVBs) to the plasma 
membrane and finally the extracellular 
environment, while exosomes are released by 
budding the plasma membrane into the 
extracellular space (34, 35). These secretory 
vesicles contain lipid, protein, mRNA, 
miRNA, noncoding RNAs and DNA 
depending on their origin. Today, the use of 
extracellular vesicles derived from MSCs has 
shown promising effects in the treatment of 
cardiovascular, hepatic, and renal disease (23, 
24). Studies have suggested that these vesicles 
have the ability to cross biological barriers 
such as the blood-brain barrier and thus they 
have been utilized for therapeutic purposes in 
several neurological diseases. For instance, 
previous studies have shown that the use of 
curcumin-enriched extracellular vesicles can 
potentially reduce inflammatory conditions in 
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the CNS (34, 36-38). It has been found that in 
pathological conditions of the nervous system 
like those in Alzheimer's, Huntington, 
Parkinson's, and Multiple Sclerosis, the 
secretion of these vesicles from damaged cells 
causes these diseases to spread (14,34). 
Almost all cells in the nervous system such as 
neurons (39-41), astrocytes (34, 41), microglia 
(41, 42) and oligodendrocyte are capable of 
secreting extracellular vesicles (41, 43). 
Recent studies have shown that exosomes 
derived from MSCs can reduce neuronal 
inflammation, encourage neural repair by 
angiogenesis and neurogenesis, and treat 
spatial learning disorders (44). These studies 
have shown that the use of exosomes in the 
treatment of brain injury is more beneficial 
than employing MSCs themselves. Unlike 
MSCs, extracellular vesicles are easy to 
transport and maintain without differentiation. 
The exact mechanism underlying the efficacy 
of exosomes over MSCs has not been 
elucidated, however, various drugs such as 
methylprednisolone with anti-inflammatory 
effects, riluzole with ion channels, G-CSF are 
used (15). 
According to a study, the effect of systemic 
injection of bone marrow MSC-derived 
exosomes on apoptosis, inflammation, and 
angiogenesis after SI was investigated (23). 
They studied how the systemic injection of 
MSC-derived exosomes could improve SCI. 
The researchers developed the model of SCI 
by contusion at the level of the T10 vertebra. 
The animals were then divided into two groups 
of normal saline and exosome recipients (30 
minutes post-injury via the tail vein). They 
extracted the exosomes from MSCs obtained 
from the bone marrow of male rats via 
ultracentrifugation. They found that the mice 
receiving exosomes had a better performance 
on the BBB test than the normal saline group. 
Furthermore, the results showed that the size 
of the lesion site was smaller in the exosome 
recipient group on 28 days post-injury (23). 
Also, in the exosome-treated group, the 
expression level of Bax protein was reduced, 
while the expression level of Bcl2 protein 
increased compared to the control group. In 
addition, in the exosome-treated group, the 
level of proinflammatory cytokines (IL-1β, 
TNF- α) decreased significantly, while the 
level of IL10 anti-inflammatory cytokines 
increased. Finally, the number of vessels in the 
exosome recipient group increased three days 
post-injury as compared with the control group 
(23). A study was conducted by Sun and 
colleagues (2018) to investigate the effect of 
umbilical cord-derived MSCs on the reduction 
of inflammation following SCI. In their study, 
they used C57BL/6 mice and developed a 
model of SCI by contusion at the level of T11-
T12 vertebrae. The researchers prepared the 
MSCs used in the study from the cord and then 
cultured them. The culture media were 
collected by ultracentrifugation to extract the 
media. They divided the animals into three 
groups receiving PBS, 20 and 200 μg of the 
exosome. Exosomes were injected into the 
caudal vein 30 minutes post-injury. Behavioral 
tests showed that the 200 µg exosome group 
showed a better performance than the PBS 
group did. Also, the volume of the cavity 
created in the spinal cord was smaller in the 
aforementioned group compared to the 20 µg 
exosome group and the PBS recipient group. 
Examination of tissue sections from the spinal 
cord by immunofluorescence revealed that the 
ratio of M2 to M1 macrophages increased in 
the exosome recipient group. The results of in-
vitro experiments also revealed that cord stem 
cell-derived exosomes are capable of 
converting M1 to M2 macrophages (45). 
In 2018, Lankford et al. examined the 
intravenous injection of bone marrow MSCs-
derived exosomes onto M2 macrophages in 
SCI. The researchers prepared and cultured 
MSCs from the bone marrow of Sprague-
Dawley rats and added them to the DiR 
medium to label the exosomes. Then, the 
media were extracted by ultracentrifugation 
from the media medium. They developed the 
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model of SCI through contusion at the level of 
the T9 vertebra. One week after injury, the 
exosomes were injected into the rats through 
the saphenous vein. They observed DiR-
labeled exosomes in the secretory and caudal 
region of the lesion at a very low level. Also, 
by reconstructing the lesion site images via a 
three-dimensional method and specific 
staining of macrophage subtypes, it was found 
that the exosomes just below the M2 group 
were macrophages (25). 
Kong and colleagues (2018) inspected the role 
of cerebrospinal fluid-derived exosomes in rats 
with SCI on in-vitro neuronal proliferation. In 
their study, they developed a model of SCI 
using the contusion method. They then 
collected cerebrospinal fluid from SCI mice 
and healthy mice and extracted the exosomes 
by ultracentrifugation. The researchers 
obtained the cells required for culture from the 
rat spinal cord. They then added them to one 
group of exosomes from SCI model mice and 
to another group of exosomes derived from 
healthy mice. They found that cells treated 
with exosomes derived from SCI mice showed 
more proliferation and increased ERK1/2 gene 
expression in these cells (3). 
Zhang and colleagues conducted a study in 
2016 to investigate the effect of exosomes 
derived from bone marrow MSCs on 
functional recovery and neurovascular 
plasticity in rats following traumatic brain 
injury. To extract the exosomes, the 
researchers utilized bone marrow MSCs and 
extracted the exosomes by the Exo-Quick-Tc 
method after culturing these cells in the culture 
medium and collecting the optimum medium. 
The researchers used Wistar rats and 
developed the TBI model in CCI. They then 
divided the animals into three groups: sham, 
TBI + Exosom, and TBI + PBS, and injected 
the exosomes through the caudate vein the day 
after injury. They observed that the injection 
of exosomes improved spatial learning in TBI 
rats. It was also found that the rats receiving 
exosomes showed better sensory-motor 
improvement than controls did. In addition, it 
was found that the extent of angiogenesis was 
significantly enhanced in the exosome 
recipient group. In addition, neurogenesis was 
significantly amplified in the hippocampal 
dentate gyrus in this group. Finally, they 
discovered that the rate of cerebral 
inflammation in the expatriate recipient group 
was significantly reduced (44). 
Elsewhere, Lai et al. (2010) examined the 
effect of exosomes secreted by MSCs on 
reducing ischemia-reperfusion injury of the 
heart muscle. The researchers cloned the 
animals to create an animal model of the left 
coronary artery and opened it 30 minutes later. 
They injected cultured media MSC cells 
containing paracrine secretions of the cells 
through the caudate vein of the animals for 5 
min before re-opening the artery. According to 
the findings of their study, they suggested that 
the protective effects of MSCs are due to their 
paracrine secretions. Their results indicated 
that the animals receiving the exosomes had 
decreased the size of the heart muscle injury 
site, suggesting the ability of the exosomes to 
repair tissue damage (31). 
Arslen et al. (2013) investigated the effect of 
MSCs-derived exosomes on ATP levels, 
oxidative stress, and the PI3K/AKT pathway 
in cardiac ischemia-reperfusion injury. In their 
study, they used C57BL6/J mice and 
developed the injury model by closing the 
animal's left coronary artery for 30 minutes 
and then re-opening it. They injected the 
extracted exosomes through the tail vein to the 
rats 5 minutes before the artery reopening. The 
results of their study showed that the 
exosomes reduced the size of the injury by 
interacting directly with the heart muscle cells. 
They also found that in the exosome recipient 
group, the left ventricular dilatation was 
prevented and cardiac function was also 
improved. In addition, their results showed 
that 30 minutes after reperfusion, the ratio of 
ATP/ADP and NADH/NAD+ increased 
significantly in the exosome recipient group, 
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but the level of oxidative stress decreased 
significantly. The researchers also noted that 
phosphorylated AKT and GSK3 were 
phosphorylated significantly in the exosome 
recipient 1 hour after reperfusion while the 
pro-apoptotic signals decreased significantly. 
Exosomes also proved to reduce inflammation 
after injury (46).  
A study to evaluate the effects of exosomes 
derived from adipose tissue-derived stem cells 
(ADSCs) on neuronal remodeling and sciatic 
nerve regeneration after injury was performed 
by Bucan and colleagues (2018). The 
researchers investigated the effects of 
exosomes on the growth of neuronal wastes in 
an in-vitro environment. They also injected the 
exosomes into the proximal and distal parts of 
the lesion after the injury to the sciatic nerve 
by Hamilton's syringe. The results of their in 
vitro studies showed that shoots in neuronal 
fractions increased significantly in the culture 
medium at 48 hours post-exposure to 
exosomes. In addition, the results of their in-
vivo study also suggested that the exosome 
recipient group showed a higher degree of 
neurodegeneration (47). 
Zhou and colleagues (2013) conducted a study 
to compare the therapeutic effects of bone 
marrow-derived stem cells with ADSC in the 
treatment of SCI. The researchers used 108 
Wistar rats and divided the animals into three 
groups: PBS recipient, hBMSC recipient, and 
hADSC recipient. They then developed SCI at 
the level of the T9 vertebra. After the injury, 
the researchers injected the cells 2 mm above 
and below the injury site. The results of their 
study showed that ADSC significantly 
expressed higher levels of HGF, VEGF, and 
BDNF than bone marrow-derived stem cells 
did. They observed that animals receiving 
hADSC experienced better angiogenesis. In 
addition, the hADSC recipient group showed 
significantly better cortical and spinal cord 
regeneration than the hBMSC recipient group 
did. Also, in both groups of recipient stem 
cells, the volume of the cavity created was 
lower than in the control group, though this 
decrease was more pronounced in the hADSC 
recipient group. Meanwhile, the activity of 
microglia/macrophage cells in both recipient 
groups was lower than in the control group. 
BBB behavioral test results were better in 
hADSC recipients than in the other two 
groups. They eventually suggested that the use 
of hADSCs was a better option to help reduce 
SCI complications than employing hBMSCs 
(48). 
Conclusion 
Taken together, the extracellular nanovesicles 
have promising therapeutic potentials and their 
use in the treatment of SCI has been rapidly 
growing. In this review, we elucidated the 
effect of exosomes derived from bone marrow 
MSCs in SCI.  
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